key: cord-0859386-bwx9x5fj authors: Marofi, Faroogh; Abdul‐Rasheed, Omar F.; Rahman, Heshu Sulaiman; Budi, Hendrik Setia; Jalil, Abduladheem Turki; Yumashev, Alexei Valerievich; Hassanzadeh, Ali; Yazdanifar, Mahboubeh; Motavalli, Roza; Chartrand, Max Stanley; Ahmadi, Majid; Cid‐Arreguid, Angel; Jarahian, Mostafa title: CAR‐NK cell in cancer immunotherapy; A promising frontier date: 2021-07-07 journal: Cancer Sci DOI: 10.1111/cas.14993 sha: 1a61e788a89482087b6872fe38c3e4db6963f840 doc_id: 859386 cord_uid: bwx9x5fj Chimeric antigen receptors (CARs) have a unique facet of synthetic biology and offer a paradigm shift in personalized medicine as they can use and redirect the patient's immune cells to attack cancer cells. CAR‐natural killer (NK) cells combine the targeted specificity of antigens with the subsequent intracellular signaling ability of the receptors to increase their anti‐cancer functions. Importantly, CAR‐NK cells can be utilized as universal cell‐based therapy without requiring human leukocyte antigen (HLA) matching or earlier contact with tumor‐associated antigens (TAAs). Indeed, CAR‐NK cells can be adapted to recognize various antigens, hold higher proliferation capacity, and in vivo persistence, show improved infiltration into the tumors, and the ability to overcome the resistant tumor microenvironment leading to sustained cytotoxicity against tumors. Accumulating evidence from recent in vivo studies rendering CAR‐NK cell anti‐cancer competencies renewed the attention in the context of cancer immunotherapy, as these redirected effector cells can be used in the development of the “off‐the‐shelf” anti‐cancer immunotherapeutic products. In the current review, we focus on the therapeutic efficacy of CAR‐NK cell therapies for treating various human malignancies, including hematological malignancies and solid tumors, and will discuss the recent findings in this regard, with a special focus on animal studies. In recent years, natural killer (NK) cells, first defined by Herberman in 1976, 1 have been described as effector cells like cytotoxic T lymphocytes (CTLs), which elicit natural cytotoxicity toward primary malignant cells and metastatic cells by suppressing the proliferation and migration of tumor cells. 2 Regardless of their cytotoxic attributes, NK cells can produce several cytokines, in particular interferonγ (IFNγ), to moderate adaptive immune responses and contribute to other associated axis. 2, 3 Most importantly, NK cells can distinguish malignant cells from healthy ones, providing a more selective anti-tumor cytotoxicity and mitigating off-target problems. Indeed, throughout development in bone marrow (BM), a process called education selects for NK cells that engage their immunoreceptor tyrosine-based inhibitory motifs (ITIMs) upon detection of major histocompatibility complex I (MHC-I), and shapes NK functional maturation and selftolerance. 4 Cancer cells, which downregulate MHC-I molecules as an immune evasion mechanism, can still be targeted by NK cells. has shown that NK cell engineering to express a chimeric antigen receptor (CAR) may defeat immune escape. [8] [9] [10] Undoubtedly, the progress of "off-the-shelf" CAR-modified NK cells is an exclusively encouraging and unique strategy by which to evolve a new generation of anti-cancer immunotherapeutic products. 10 CAR-NK cells kill cancer cells not only via CAR, which selectively identifies TAAs, but also via NK cell receptors themselves. Recent preclinical and clinical studies have supported the idea that CAR-NK cell therapy can exert the desired outcomes in both human hematological and solid malignancies, signifying their broad clinical applications. [11] [12] [13] Here, we will highlight the importance of the development of CAR-NK cell therapy as an innovative strategy in the context of cancer immunotherapy, and provide a brief overview of the recent findings on CAR-NK cell therapy in human malignancies, focusing on preclinical studies. NK cell identification of cancerous cells is a firmly controlled procedure comprising the communication of particular ligands on the cancerous cells with NK cell receptors and resulting elicitation of signals derived from these receptors in the effector NK cells. 14 Direct cancer cell elimination by NK cells is believed to be mainly perforin dependent, as widely evidenced in a variety of experimental model systems. Nonetheless, NK cells can also eradicate tumor cells by death receptor-mediated axes including tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL). 15 Moreover, effector NK cells secrete various cytokines and chemokines, which trigger other innate and adaptive immune cells responses. NK cell-mediated elimination of primary acute myeloid leukemia (AML) blasts has been shown with several NK cell preparations such as in vitro-expanded allogeneic NK cells. [16] [17] [18] It seems that killer cell immunoglobulin-like receptors (KIR) mismatching with their ligand (KIR-L) largely contributes to cancer cell lysis. Regardless of the supportive role of NKG2D in NK cell-mediated immunosurveillance of human cancers, its role in NK cell proliferation and development is debatable. Some studies in NKG2D-deficient mice revealed that NKG2D is not required for NK cell proliferation but that it is crucial for immunosurveillance of epithelial and lymphoid malignancies in transgenic models. In addition, in a prostate tumor model, aggressive tumors established in NKG2D-deficient mice showed more prominent levels of NKG2D ligands compared with similar tumors in wild-type mice, indicating a lack of selective pressure by NKG2D-mediated responses. [21] [22] [23] [24] Other reports delivered proof for the importance of NKG2D in NK cell growth and suggested that the lack of the NKG2D resulted in stunted proliferation of NK cells, and further reinforced their susceptibilities to apoptosis. 25 and also other types of cells presented in TME can stimulate suppressive effects on NK cell functions and proliferation. Nonetheless, using chimeric antigen receptor-natural killer (CAR-NK) cells can result in overcoming the NK cell dysfunction in TME. Moreover, engineered CAR-NK cells to overexpress specific chemokine receptors can support the CAR-NK cell more proficient homing to tumor tissue and accordingly may lead to more reliable therapeutic outcomes In addition to leukemia, redirected CAR-NK cells can also support favorable outcomes in lymphomas and myelomas. The EGF receptor (EGFR) is a well known tyrosine kinase receptor and remains at the front of targeted therapies toward tumors. In addition, reports have shown that EGFR-specific CAR-NK-92 cells and also primary NK cells-exerted notable cytotoxicity and IFNγ Based on collective evidence, CAR-NK cell-based cancer therapy has become an encouraging and advanced research area. Accordingly, a wide spectrum of animal studies has been carried out (Table 1) including IL-1, IL-2, IL-6, TNFα, IL-8, IL-10, and IL-15, which generally support CRS and severe neurotoxicity. 10 In addition, the attenuated risk for GVHD occurrence even with allogeneic NK cells possibly permits CAR-NK cells to be established from several sources, such as NK92 cell lines, PBMCs, UCB, and also pluripotent stem cells. 60 Although a great deal of progress has been achieved in NK cell immunotherapy, clinical efficacy is still limited due to the short lifespan and low cytotoxicity of NK cells in vivo, highlighting the importance of finding a novel approach for overcoming this challenge. However, the risk of on-target/off-tumor toxicity to normal tissues is comparatively low because of the restricted lifespan of CAR-NK cells in the circulation. 61 In sum, it is speculated that the development of the CAR construction for superior NK cell-elicited cytotoxicity, improving redirected cell infiltration into tumor microenvironments (TME), concomitant with developing CAR-NK cells with memory phenotypes to offer prolonged immune surveillance, can lead to the desired anti-cancer outcomes. There is no conflict of interests. Faroogh Marofi https://orcid.org/0000-0002-8110-7808 Abduladheem Turki Jalil https://orcid. org/0000-0001-8403-7465 Cellmediated immunity to leukemia virus-and tumor-associated antigens in mice NK cells and ILCs in tumor immunotherapy Natural killer cell lines in tumor immunotherapy NK cell education: not an on-off switch but a tunable rheostat Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients From tumor cell metabolism to tumor immune escape CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs) Off-the-shelf CAR-NK cells for cancer immunotherapy Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia Natural killer cells in liver disease and hepatocellular carcinoma and the NK Cell-based immunotherapy Natural killer cell-mediated immunosurveillance of human cancer Ex vivo expanded adaptive NK cells effectively kill primary acute lymphoblastic leukemia cells NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Risk of COVID-19 for patients with cancer: A narrative overview NK cells and cancer immunosurveillance In vivo natural killer cell activities revealed by natural killer cell-deficient mice NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy Belinostat effects on expression of RBM5 tumor suppressor gene and inhibits prostate cancer cell line (PC3) proliferation Total Phenolic Content, Antioxidant and Cyto-/Genotoxic Activities of Pelargonium Quercetorum Agnew in Human Breast Cancer Cells A silent potent killer Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice Crosstalk between cancerassociated fibroblasts and immune cells in cancer Myeloid derived suppressor cells interactions with natural killer cells and proangiogenic activities: Roles in tumor progression Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Proangiogenic Activities: Roles in Tumor Progression Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity Coping with Women's Cancer and Perceived Providers' Support: Does Type of Cancer Make a Difference? Toll-like receptors on tumor cells facilitate evasion of immune surveillance CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing Strategies to Address Chimeric Antigen Receptor Tonic Signaling Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Clinical grade purification and expansion of natural killer cells Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells A novel CD7 chimeric antigen receptormodified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobodybased chimeric antigen receptors (Nb-CARs) Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases Targeting epidermal growth factoroverexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts Modulation of anti-tumour activity of ex vivo expanded NK and GD2CAR-NK cells against neuroblastoma Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of Hepatocellular Carcinoma Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D CAR-NK for tumor immunotherapy: Clinical transformation and future prospects Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells. Zhongguo shi yan xue ye xue za zhi Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells HER2-specific chimeric antigen receptorengineered natural killer cells combined with apatinib for the treatment of gastric cancer ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma Combination therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptorexpressing natural killer/innate lymphoid cells Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells